Biblio

Author Title [ Type

] Year

Filters: First Letter Of Title is O [Clear All Filters]

Journal Article

Razonable RR. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clin Microbiol Infect. 2023.

Minoia C, Diella L, Perrone T, Loseto G, Pelligrino C, Attolico I, Pasciolla C, Totaro V, De Candia MStella, Spada V, et al. Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: A multicentre prospective cohort. Br J Haematol. 2023.

Kalff A, Khong T, Mithraprabhu S, Bergin K, Reynolds J, Bowen KM, Thakurta A, Guzman R, Wang M, Couto S, et al. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leuk Lymphoma. 2019:1-9.

Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2023.

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang J-H, Porkka K, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020;383(26):2526-2537.

Ohshima H, Mishima K, Amizuka N. Oral Biosciences: The annual review 2021. J Oral Biosci. 2022.

Ohshima H, Mishima K. Oral Biosciences: The annual review 2022. J Oral Biosci. 2023.

de Araújo RLins Fuent, Lyko Kde Fátima, Funke VAraújo Mo, Torres-Pereira CCarvalho. Oral cancer after prolonged immunosuppression for multiorgan chronic graft-versus-host disease. Rev Bras Hematol Hemoter. 2014;36(1):65-8.

Al-Magsoosi MJN, Lambert DW, Khurram SAli, Whawell SA. Oral cancer stem cells drive tumourigenesis through activation of stromal fibroblasts. Oral Dis. 2020.

Mauramo M, Tonoz N, Halter J, Joseph B, Waltimo T. Oral Candida carriage and resistance against common antifungal agents in hematopoietic stem cell transplantation recipients. Support Care Cancer. 2024;32(3):185.

Botari CMarino Esp, Nunes AJosé Ferr, de Souza MPedro, Orti-Raduan ESinara Len, Salvio AGabriela. Oral chronic graft-versus-host disease: analysis of dendritic cells subpopulations. An Bras Dermatol. 2014;89(4):632-637.

Epstein JB, Hernandez RS, Nakamura R, Yost SE, Ali H. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports. Case Rep Oncol. 2023;16(1):1287-1292.

Braber JBos-den, Potting CMJ, Bronkhorst EM, Huysmans M-CDNJM, Blijlevens NMA. Oral complaints and dental care of haematopoietic stem cell transplant patients: a qualitative survey of patients and their dentists. Support Care Cancer. 2014.

Valéra M-C, Noirrit-Esclassan E, Pasquet M, Vaysse F. Oral complications and dental care in children with acute lymphoblastic leukaemia. J Oral Pathol Med. 2014.

Wong HMing. Oral Complications and Management Strategies for Patients Undergoing Cancer Therapy. ScientificWorldJournal. 2014;2014:581795.

Haverman TM, Raber-Durlacher JE, Rademacher WMH, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR. Oral Complications in Hematopoietic Stem Cell Recipients: The Role of Inflammation. Mediators Inflamm. 2014;2014:378281.

Fall-Dickson JM, Pavletic SZ, Mays JW, Schubert MM. Oral Complications of Chronic Graft-Versus-Host Disease. J Natl Cancer Inst Monogr. 2019;2019(53).

Riley P, McCabe MG, Glenny A-M. Oral Cryotherapy for Preventing Oral Mucositis in Patients Receiving Cancer Treatment. JAMA Oncol. 2016.

Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024.

Kim D-W, Jeong H-S, Kim E, Lee H, Choi C-H, Lee S-J. Oral delivery of stem-cell-loaded hydrogel microcapsules restores gut inflammation and microbiota. J Control Release. 2022.

Xu K, Ren Y, Zhao S, Feng J, Wu Q, Gong X, Chen J, Xie P. Oral D-ribose causes depressive-like behavior by altering glycerophospholipid metabolism via the gut-brain axis. Commun Biol. 2024;7(1):69.

Bhutani U, Basu T, Majumdar S. Oral drug delivery: Conventional to Long Acting New-Age Designs. Eur J Pharm Biopharm. 2021.

Guler E, Hazar-Yavuz ANur, Tatar E, Haidari MMorid, Ozcan GSinemcan, Duruksu G, Graça MPedro F, Kalaskar DM, Gunduz O, Cam MEmin. Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri- axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. Int J Pharm. 2023:122716.

Shimizu S, Maeda N, Takahashi Y, Uomoto S, Takesue K, Ojiro R, Tang Q, Ozawa S, Okano H, Takashima K, et al. Oral exposure to aluminum chloride for 28 days suppresses neural stem cell proliferation and increases mature granule cells in adult hippocampal neurogenesis of young-adult rats. J Appl Toxicol. 2022.

Lumbikananda S, Srithanyarat SSuphananta, Mattheos N, Osathanon T. Oral Fluid Biomarkers for Peri-Implantitis: A Scoping Review. Int Dent J. 2023.

Pages